Stock Scorecard



Stock Summary for Viking Therapeutics Inc (VKTX) - $18.48 as of 12/9/2023 2:42:26 AM EST

Total Score

10 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for VKTX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for VKTX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for VKTX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for VKTX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for VKTX

Why Viking Therapeutics Was Crushing It This Week 12/8/2023 1:14:00 PM
What's Going On With Viking Therapeutics Shares Tuesday? - Viking Therapeutics ( NASDAQ:VKTX ) 11/14/2023 4:42:00 PM
Viking Therapeutics Sees RS Rating Climb To 72 11/14/2023 8:00:00 AM
1 Under-the-Radar Stock That Could Triple By 2030 11/4/2023 11:30:00 AM
Stocks With Rising Relative Price Strength: Viking Therapeutics 10/24/2023 7:00:00 AM
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity 10/23/2023 11:05:00 AM
Why Talaris Therapeutics Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Biocept ( NASDAQ:BIOC ) , Advent Technologies Hldgs ( NASDAQ:ADN ) 10/18/2023 12:18:00 PM
Stock movers: United Airlines shares drop after warning on fuel costs and Middle East conflict 10/18/2023 9:57:00 AM
Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023 10/17/2023 8:05:00 PM
Akero ( AKRO ) Slumps 63% on Mixed Results From NASH Study 10/11/2023 3:11:00 PM

Financial Details for VKTX

Company Overview

Ticker VKTX
Company Name Viking Therapeutics Inc
Country USA
Description Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2023
Next Earnings Date 2/6/2024

Stock Price History

Last Day Price 18.48
Last Day Price Updated 12/9/2023 2:42:26 AM EST
Last Day Volume 0
Average Daily Volume N/A
52-Week High 25.72
52-Week Low 3.54
Last Price to 52 Week Low 422.03 %

Valuation Measures

Trailing PE N/A
Industry PE 57.56
Sector PE 62.37
5-Year Average PE -13.19
Free Cash Flow Ratio 4.91
Industry Free Cash Flow Ratio 10.37
Sector Free Cash Flow Ratio 31.15
Current Ratio Most Recent Quarter 28.44
Total Cash Per Share 3.76
Book Value Per Share Most Recent Quarter 3.68
Price to Book Ratio 5.02
Industry Price to Book Ratio 4.33
Sector Price to Book Ratio 19.59
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 10.29
Sector Price to Sales Ratio Twelve Trailing Months 5.61

Share Statistics

Total Shares Outstanding 100,029,000
Market Capitalization 1,848,535,920
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Dividend King? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00 %
5-Year Dividend Payments Count 0
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00 %
Annual Earnings Growth -25.24 %
Reported EPS 12 Trailing Months -0.92
Reported EPS Past Year -0.67
Reported EPS Prior Year -0.91
Net Income Twelve Trailing Months -80,849,000
Net Income Past Year -68,867,000
Net Income Prior Year -54,990,000
Quarterly Revenue Growth YOY 0.00 %
5-Year Revenue Growth 0.00 %

Balance Sheet

Total Cash Most Recent Quarter 376,241,000
Total Cash Past Year 155,485,000
Total Cash Prior Year 202,103,000
Net Cash Position Most Recent Quarter 376,241,000
Net Cash Position Past Year 155,485,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 145,322,000
Total Stockholder Equity Prior Year 201,884,000
Total Stockholder Equity Most Recent Quarter 368,240,000

Options

Put/Call Ratio 0.20
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 1.38
MACD Signal 0.69
20-Day Bollinger Lower Band 8.37
20-Day Bollinger Middle Band 12.81
20-Day Bollinger Upper Band 17.26
Beta 0.61
RSI 83.48
50-Day SMA 14.24
200-Day SMA 7.52

System

Modified 12/10/2023 1:31:29 AM EST